Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors
Semin Arthritis Rheum. 2025;73:152737 doi: 10.1016/j.semarthrit.2025.152737
Haddad et al. used real-world data from Israel’s largest health maintenance organisation to investigate predictors and patterns of biologic therapy switching in PsA, reporting that nearly half of biologic users switched therapy at least once. Cross-class switching, particularly from anti-TNF to IL-17 therapies, was frequent and consistent across two decades of treatment data.
This retrospective cohort study included 3851 PsA patients initiating biologics between 2005 and 2023 within the Clalit Health Services database. Key predictors of MoA switching included female sex, obesity, smoking, and lower socioeconomic status. The study highlighted switching trends and identified independent risk factors to optimise treatment.
Keywords:
